focus -WSS

focus

author：explore 2025-09-03 18:41:15 - browse：5297

A liver with a smooth and healthy left half and a bumpy, browning right half — chronic disease coverage from STAT — Adobe

Akero Therapeutics said Monday that extending treatment with its experimental drug for the liver disease known as MASH from six months to two years resulted in better outcomes for patients — most notably reductions in liver scarring at a rate three times higher than placebo without worsening other symptoms.

The mid-stage study of the Akero drug called efruxifermin achieved its main goal in September 2022. With longer treatment, more patients with MASH responded to the drug, while those who initially benefited showed durable improvements.

“We’re really pleased with the data. It’s exactly what we were hoping to see,” said Kitty Yale, Akero’s chief development officer, in an interview with STAT. “It’s not just the high response rates, but the fact that responses are sustained and broadened as well.”

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： At least 13 dead in Texas as scorching temps continue
Next article： Colorectal cancer study finds potential in overlooked immune cell

WSS

Stroke deaths set to near 10 million globally by 2050

Analysis of telehealth claims data suggest service duplication

FDA authorizes Novavax’s updated Covid

In early work, researchers turn to CRISPR to treat Alzheimer's

Key House panel plots a new health care package

Stroke deaths set to near 10 million globally by 2050

hotspot

focus

hotspot

Medicare details structure of new drug price negotiation program

3 questions for the future of Biden's cancer moonshot

At least 13 dead in Texas as scorching temps continue

Why age limits for politicians are a terrible idea

Medicare proposal to cover medical devices draws a mixed reaction

Colorectal cancer study finds potential in overlooked immune cell

Peter Hotez and the public health issue of online harassment

Analysis of telehealth claims data suggest service duplication

Novavax promises a turnaround & Lilly roils the obesity market

VC firm General Catalyst wants to buy a health system

focus

Why hospitals are withdrawing from US News rankings

Physician executives need more than on

In early work, researchers turn to CRISPR to treat Alzheimer's

Bill would stop addiction treatment from triggering child abuse inquiry

Medicare has a new plan to address drug shortages

Bristol 'take

focus

knowledge

leisure time

knowledge